We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

142 hedge funds and large institutions have $2B invested in Apellis Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 37

30% more capital invested

Capital invested by funds: $1.53B → $2B (+$464M)

22% more call options, than puts

Call options by funds: $8.24M | Put options by funds: $6.76M

5.17% more ownership

Funds ownership: 75.86% → 81.03% (+5.2%)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

1% less funds holding

Funds holding: 143 → 142 (-1)

Holders
142
Holders Change
-1
Holders Change %
-0.7%
% of All Funds
2.91%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
16
Increased
72
Reduced
37
Closed
15
Calls
$8.24M
Puts
$6.76M
Net Calls
+$1.48M
Net Calls Change
+$7.54M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$57.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$43.5M
3
CS
Candriam SCA
Luxembourg
+$26.3M
4
Citadel Advisors
Citadel Advisors
Florida
+$20.4M
5
State Street
State Street
Massachusetts
+$14.4M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$56.8M
2
EP
Eversept Partners
New York
-$15.4M
3
Millennium Management
Millennium Management
New York
-$9.07M
4
Norges Bank
Norges Bank
Norway
-$9M
5
CAM
Cormorant Asset Management
Massachusetts
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
51
California State Teachers Retirement System (CalSTRS)
California
$2.96M +$115K +3,572 +4%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$2.95M +$418K +13,003 +17%
Prudential Financial
53
Prudential Financial
New Jersey
$2.92M +$25.4K +792 +0.9%
Susquehanna International Group
54
Susquehanna International Group
Pennsylvania
$2.9M -$1.19M -37,133 -30%
AllianceBernstein
55
AllianceBernstein
Tennessee
$2.67M +$209K +6,500 +9%
Jacobs Levy Equity Management
56
Jacobs Levy Equity Management
New Jersey
$2.6M +$2.55M +79,512 New
BCM
57
Burrage Capital Management
Massachusetts
$2.43M – – –
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$2.37M -$57.3K -1,785 -2%
PAG
59
Private Advisor Group
New Jersey
$2.33M +$2.73K +85 +0.1%
Citigroup
60
Citigroup
New York
$2.21M +$493K +15,336 +29%
TD Asset Management
61
TD Asset Management
Ontario, Canada
$2.18M +$1.14M +35,500 +114%
UBS AM
62
UBS AM
Illinois
$2.14M +$590K +18,383 +39%
Barclays
63
Barclays
United Kingdom
$2.07M -$4.06M -126,534 -67%
State of New Jersey Common Pension Fund D
64
State of New Jersey Common Pension Fund D
New Jersey
$1.98M -$550K -17,133 -22%
Morgan Stanley
65
Morgan Stanley
New York
$1.84M +$216K +6,730 +14%
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
$1.8M +$138K +4,300 +8%
MSL
67
Mackay Shields LLC
New York
$1.79M +$549K +17,100 +45%
AA
68
Aufman Associates
Pennsylvania
$1.75M – – –
SI
69
Sofinnova Investments
California
$1.62M – – –
AG
70
Algert Global
California
$1.57M -$56.2K -1,750 -4%
Arrowstreet Capital
71
Arrowstreet Capital
Massachusetts
$1.38M +$93.1K +2,900 +7%
Wells Fargo
72
Wells Fargo
California
$1.33M +$316K +9,828 +32%
AIG
73
American International Group
New York
$1.2M +$91.5K +2,850 +8%
CSS
74
Cubist Systematic Strategies
Connecticut
$1.2M +$340K +10,597 +41%
Russell Investments Group
75
Russell Investments Group
United Kingdom
$1.12M +$401K +12,492 +57%
1 2
3
4 5

APLS Hedge Fund Activity: Q2 2020 in Review

142 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2020, worth a combined $2B — up 30% from $1.53B a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new APLS positions and 15 closed out — a net gain of 1 holder — while 72 added to existing stakes and 37 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $57.1M. The largest seller was Victory Capital Management, cutting an estimated $56.8M.

  • 142 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2020, down from 143 in Q1 2020.
  • Funds reported $2B of Apellis Pharmaceuticals stock for Q2 2020, up 30% quarter-over-quarter.
  • 16 funds opened new Apellis Pharmaceuticals positions in Q2 2020 and 15 closed out, a net change of +1 holder.
  • The largest Apellis Pharmaceuticals buyer in Q2 2020 was T. Rowe Price Associates, an estimated $57.1M added.
  • The largest Apellis Pharmaceuticals seller in Q2 2020 was Victory Capital Management, an estimated $56.8M sold.

Based on aggregated 13F filings for Q2 2020.